Last reviewed · How we verify
FBS0701
At a glance
| Generic name | FBS0701 |
|---|---|
| Sponsor | FerroKin BioSciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function (PHASE1)
- Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184) (PHASE2)
- AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184 (PHASE1)
- Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload (PHASE2)
- Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function (PHASE1)
- Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FBS0701 CI brief — competitive landscape report
- FBS0701 updates RSS · CI watch RSS
- FerroKin BioSciences, Inc. portfolio CI